Administration of Tubulin inhibitor 11 at doses of 5 to 10 mg/kg orally once daily exhibits robust antitumor efficacies in vivo^[1].

Exposure to Tubulin inhibitor 11 at concentrations ranging from 0.03 to 0.1 μM for 12 hours results in cell cycle arrest at the G2/M phase. Additionally, Tubulin inhibitor 11 reduces cdc2 phosphorylation and increases cyclin B1 and phosphorylation of histone H3 at Ser10 in cells ^[1].

Treatment with Tubulin inhibitor 11 at concentrations ranging from 0.03 to 0.3 μM for 48 hours induces apoptosis in cancer cells ^[1].

Tubulin inhibitor 11 demonstrates favorable antiproliferative activities in DU145 cells, with an IC50 of 8 nM ^[1].

Moreover, Tubulin inhibitor 11 at concentrations ranging from 0.03 to 0.3 μM significantly reduces the expression levels of acetyl-α-tubulin and α-tubulin in a dose-dependent manner ^[1].